The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
Open accessAbstract
A panel of anti-gp120 human monoclonal antibodies (HuMAbs), CD4-IgG, and sera from people infected with human immunodeficiency virus type 1 (HIV-1) was tested for neutralization of nine primary HIV-1 isolates, one molecularly cloned primary strain (JR-CSF), and two strains (IIIB and MN) adapted for growth in transformed T-cell lines. All the viruses were grown in mitogen-stimulated peripheral blood mononuclear cells and were tested for their ability to infect these cells in the presence and absence of the reagents mentioned above. In general, the primary isolates were relatively resistant to neutralization by the MAbs tested, compared with the T-cell line-adapted strains. However, one HuMAb, IgG1b12, was able to neutralize most of the primary isolates at concentrations of < or = 1 microgram/ml. Usually, the inability of a HuMAb to neutralize a primary isolate was not due merely to the absence of the antibody epitope from the virus; the majority of the HuMAbs bound with high affinity to monomeric gp120 molecules derived from various strains but neutralized the viruses inefficiently. We infer therefore that the mechanism of resistance of primary isolates to most neutralizing antibodies is complex, and we suggest that it involves an inaccessibility of antibody binding sites in the context of the native glycoprotein complex on the virion. Such a mechanism would parallel that which was previously postulated for soluble CD4 resistance. We conclude that studies of HIV-1 neutralization that rely on strains adapted to growth in transformed T-cell lines yield the misleading impression that HIV-1 is readily neutralized. The more relevant primary HIV-1 isolates are relatively resistant to neutralization, although these isolates can be potently neutralized by a subset of human polyclonal or monoclonal antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., & Ho, D. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4650-4655.1994 · Cited by 2,495
Self-citationGenotypic and Phenotypic Characterization of HIV-1 Patients with Primary Infection
Zhu, T., Mo, H., Wang, N., Nam, D. S., Cao, Y., Koup, R. A., & Ho, D. D. (1993) · Science · doi:10.1126/science.8356453 · Cited by 1,249
Self-citationPrincipal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
Javaherian, K., Langlois, A. J., McDanal, C., Ross, K. L., Eckler, L. I., Jellis, C. L., Profy, A. T., Rusche, J. R., Bolognesi, D. P., & Putney, S. D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6768 · Cited by 618
Designing CD4 immunoadhesins for AIDS therapy
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. (1989) · Nature · doi:10.1038/337525a0 · Cited by 615
Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., & Eichberg, J. W. (1990) · Nature · doi:10.1038/345622a0 · Cited by 590
O'Brien, W. A., Koyanagi, Y., Namazie, A., Zhao, J.-Q., Diagne, A., ldler, K., Zack, J. A., & Chen, I. S. Y. (1990) · Nature · doi:10.1038/348069a0 · Cited by 570
Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., & Burton, D. R. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.4821-4828.1994 · Cited by 455
Self-citationNeutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients
Weiss, R. A., Clapham, P. R., Cheingsong-Popov, R., Dalgleish, A. G., Carne, C. A., Weller, I. V. D., & Tedder, R. S. (1985) · Nature · doi:10.1038/316069a0 · Cited by 452
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex
Robert-Guroff, M., Brown, M., & Gallo, R. C. (1985) · Nature · doi:10.1038/316072a0 · Cited by 431
Broadly Neutralizing Antibodies Elicited by the Hypervariable Neutralizing Determinant of HIV-1
Javaherian, K., Langlois, A. J., LaRosa, G. J., Profy, A. T., Bolognesi, D. P., Herlihy, W. C., Putney, S. D., & Matthews, T. J. (1990) · Science · doi:10.1126/science.1703322 · Cited by 353
Cited by
An HIV Vaccine — Evolving Concepts
Johnston, M. I., & Fauci, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066267 · Cited by 257
Sequencing the biology of entry: the retroviral Env gene
Swanstrom, R., Graham, W. D., & Zhou, S. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_35 · Cited by 24
Metadata
- Authors
- Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., Burton, D. R., & Ho, D. D.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 1995-01
- Volume
- 69
- Issue
- 1
- Pages
- 101-109
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2138634802
- Cited by
- 401
- References
- 41
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. https://app.cochat.ai/papers/10.1128/jvi.69.1.101-109.1995
- The paper
- Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., Burton, D. R., & Ho, D. D. (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology. https://doi.org/10.1128/jvi.69.1.101-109.1995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.